|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cancer treatment and survivorship statistics, 2012显示文摘 | Rebecca Siegel Carol DeSantis Katherine Virgo Kevin Stein Angela Mariotto Tenbroeck Smith Dexter Cooper Ted Gansler Catherine Lerro Stacey Fedewa Chunchieh Lin Corinne Leach Rachel Spillers Cannady Hyunsoon Cho Steve Scoppa Mark Hachey Rebecca Kirch Ahmed | 2012 | CA: A Cancer Journal for Clinicians2012，，4： | 6 |
| 2 | End-stage renal disease is associated with increased post endoscopic retrograde cholangiopancreatography adverse events in hospitalized patients显示文摘AIM To determine if end-stage renal disease (ESRD) is a risk factor for post endoscopic retrograde cholangio-pancreatography (ERCP) adverse events (AEs). METHODS We performed a retrospective cohort study using the Nationwide Inpatient Sample (NIS) 2011-2013. We identified adult patients who underwent ERCP using the International Classification of Diseases 9^(th) Revision (ICD-9-CM). Included patients were divided into three groups: ESRD, chronic kidney disease (CKD), and control. The primary outcome was post-ERCP AEs including pancreatitis, bleeding, and perforation determined based on specific ICD-9-CM codes. Secondary outcomes were length of hospital stay, in-hospital mortality, and admission cost. AEs and mortality were compared using multivariate logistic regression analysis.RESULTS There were 492175 discharges that underwent ERCP during the 3 years. The ESRD and CKD groups contained 7347 and 39403 hospitalizations respectively, whereas the control group had 445424 hospitalizations. Post-ERCP pancreatitis (PEP) was significantly higher in the ESRD group (8.3%) compared to the control group (4.6%) with adjusted odd ratio (aOR) = 1.7 (95% CI: 1.4-2.1, ~aP < 0.001). ESRD was associated with significantly higher ERCP-related bleeding (5.1%) compared to the control group 1.5% (aOR = 1.86, 95%CI: 1.4-2.4, ~aP < 0.001). ESRD had increased hospital mortality 7.1% vs 1.15% in the control OR = 6.6 (95%CI: 5.3-8.2, ~aP < 0.001), longer hospital stay with adjusted mean difference (aMD) = 5.9 d (95% CI: 5.0-6.7 d, ~aP < 0.001) and higher hospitalization charges aMD = $+82064 (95%CI: $68221-$95906, ~aP < 0.001). CONCLUSION ESRD is a risk factor for post-ERCP AEs and is associated with higher hospital mortality. Careful selection and close monitoring is warranted to improve outcomes. | Tarek Sawas Fateh Bazerbachi Samir Haffar Won K Cho Michael J Levy John A Martin Bret T Petersen Mark D Topazian Vinay Chandrasekhara Barham K Abu Dayyeh | 2018 | World Journal of Gastroenterology2018，24，41： | 2 |
| 3 | Cancer treatment and survivorship statistics, 2012显示文摘 | Rebecca Siegel Carol DeSantis Katherine Virgo Kevin Stein Angela Mariotto Tenbroeck Smith Dexter Cooper Ted Gansler Catherine Lerro Stacey Fedewa Chunchieh Lin Corinne Leach Rachel Spillers Cannady Hyunsoon Cho Steve Scoppa Mark Hachey Rebecca Kirch Ahmed | 2012 | CA: A Cancer Journal for Clinicians2012，，4： | 2 |
| 4 | Resection of Hilar Cholangiocarcinoma: Concomitant Liver Resection Decreases Hepatic Recurrence显示文摘 | Fumito Ito Rashmi Agni Robert J. Rettammel Mark J. Been Clifford S. Cho David M. Mahvi Layton F. Rikkers Sharon M. Weber | 2008 | Annals of Surgery2008，，2： | 1 |
| 5 | Turnover of new graduate nurses in their first job using survival analysis显示文摘 | Cho SH Lee JY Mark BA | | 0，，1： | 1 |
| 6 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 7 | Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions显示文摘 | Cho MarK Eimoto T Tateyama H | 2006 | Histopathology2006，48，3： | 1 |
| 8 | Prospective Study of Postoperative Lumbar Epidural Hematoma: Incidence and Risk Factors显示文摘 | Mark J. Sokolowski Timothy A. Garvey John Perl Margaret S. Sokolowski Woojin Cho Amir A. Mehbod Daryll C. Dykes Ensor E. Transfeldt | 2008 | Spine2008，，1： | 1 |
| 9 | Resection of Hilar Cholangiocarcinoma: Concomitant Liver Resection Decreases Hepatic Recurrence显示文摘 | Fumito Ito Rashmi Agni Robert J. Rettammel Mark J. Been Clifford S. Cho David M. Mahvi Layton F. Rikkers Sharon M. Weber | 2008 | Annals of Surgery2008，，2： | 1 |
| 10 | Hardware - sensitive optimization for intensity modulated radiotherapy显示文摘 | Cho PS Marks RJ | 2000 | Phys Med Binl2000，45，： | 1 |
| 11 | Turnover of new graduate nurses in their first job using survival analysis显示文摘 | Cho SH Lee JY Mark BA | 2012 | J Nurs scholarsh2012，44，1： | 1 |
| 12 | Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions 显示文摘 | Cho MarK Eimoto T Tateyama H etal | 2006 | Histopathology2006，48，3： | 1 |
| 13 | Supplying the trip to antibody production-nutrients,signaling,and the programming of cellular metabolism in the mature B lineage显示文摘The COVID pandemic has refreshed and expanded recognition of the vital role that sustained antibody(Ab)secretion plays in our immune defenses against microbes and of the importance of vaccines that elicit Ab protection against infection.With this backdrop,it is especially timely to review aspects of the molecular programming that govern how the cells that secrete Abs arise,persist,and meet the challenge of secreting vast amounts of these glycoproteins.Whereas plasmablasts and plasma cells(PCs)are the primary sources of secreted Abs,the process leading to the existence of these cell types starts with naive B lymphocytes that proliferate and differentiate toward several potential fates.At each step,cells reside in specific microenvironments in which they not only receive signals from cytokines and other cell surface receptors but also draw on the interstitium for nutrients.Nutrients in turn influence flux through intermediary metabolism and sensor enzymes that regulate gene transcription,translation,and metabolism.This review will focus on nutrient supply and how sensor mechanisms influence distinct cellular stages that lead to PCs and their adaptations as factories dedicated to Ab secretion.Salient findings of this group and others,sometimes exhibiting differences,will be summarized with regard to the journey to a distinctive metabolic program in PCs. | Mark R.Boothby Shawna K.Brookens Ariel L.Raybuck Sung Hoon Cho | 2022 | Cellular & Molecular Immunology2022，19，3： | 1 |
| 14 | Structural analysis for the 4-m Advanced Technology Solar Telescope(ATST)显示文摘 | CHO Myung K WARNER Mark LEE Joon Pyo | 2005 | Proceedings ofSPIE2005，5877，： | 1 |
| 15 | Comparison of Two-Dimensional Speckle and Tissue Velocity Based Strain and Validation With Harmonic Phase Magnetic Resonance Imaging显示文摘 | Goo-Yeong Cho Jonathan Chan Rodel Leano Mark Strudwick Thomas H. Marwick | 2006 | The American Journal of Cardiology2006，，11： | 1 |
| 16 | DSG2 Mutations Contribute to Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy显示文摘 | Mark M. Awad Darshan Dalal Eunpi Cho Nuria Amat-Alarcon Cynthia James Crystal Tichnell April Tucker Stuart D. Russell David A. Bluemke Harry C. Dietz Hugh Calkins Daniel P. Judge | 2006 | The American Journal of Human Genetics2006，，1： | 1 |
| 17 | An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors显示文摘 | Antony W Burgess Hyun-Soo Cho Charles Eigenbrot Kathryn M Ferguson Thomas P.J Garrett Daniel J Leahy Mark A Lemmon Mark X Sliwkowski Colin W Ward Shigeyuki Yokoyama | 2003 | Molecular Cell2003，，3： | 1 |
| 18 | Comparison of Two-Dimensional Speckle and Tissue Velocity Based Strain and Validation With Harmonic Phase Magnetic Resonance Imaging显示文摘 | Goo-Yeong Cho Jonathan Chan Rodel Leano Mark Strudwick Thomas H. Marwick | 2006 | The American Journal of Cardiology2006，，11： | 1 |
| 19 | Conformal radiotherapy computation by the method of alternating projections onto convex sets显示文摘 | Lee S Cho PS Marks R J | 1997 | Phys Med Biol1997，42，： | 1 |
| 20 | A Multi-institutional Analysis of Open Versus Minimally-Invasive Surgery for Gastric Adenocarcinoma: Results of the US Gastric Cancer Collaborative显示文摘 | Gaya Spolverato Yuhree Kim Aslam Ejaz Vicente Valero Malcolm H. Squires George Poultsides Ryan C. Fields Mark Bloomston Sharon M. Weber Alexandra W. Acher Konstantinos Votanopoulos Carl Schmidt Clifford S. Cho Shishir K. Maithel Timothy M. Pawlik | 2014 | Journal of Gastrointestinal Surgery2014，，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员